The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

micropointbio.cn

Founded Year

2007

Stage

IPO | IPO

Date of IPO

1/7/2016

About Micropoint Bioscience

Micropoint Bioscience (NEEQ: 835054) is a global provider of rapid, accurate, point-of-care testing (POCT) systems and solutions.

Micropoint Bioscience Headquarter Location

Block 6 No.3 Shekou Industrial Wu Road

Shenzhen, Guangdong, 518067,

China

+86 755 86296766

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Micropoint Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Micropoint Bioscience is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

8,286 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

3,095 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Health

12,812 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

Micropoint Bioscience Patents

Micropoint Bioscience has filed 2 patents.

The 3 most popular patent topics include:

  • Fluid dynamics
  • Molecular biology
  • Analytical chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/14/2018

11/23/2021

Fluid dynamics, Analytical chemistry, Fluid mechanics, Molecular biology, Chromatography

Grant

Application Date

6/14/2018

Grant Date

11/23/2021

Title

Related Topics

Fluid dynamics, Analytical chemistry, Fluid mechanics, Molecular biology, Chromatography

Status

Grant

Latest Micropoint Bioscience News

Bio-Techne Signs Strategic Cooperation Agreement with Micropoint

Oct 12, 2018

-Accelerating innovative tools available for precision medicine HONG KONG, Oct. 12, 2018 /PRNewswire/ -- Bio-Techne Corporation of Minneapolis, Minnesota and Micropoint Bioscience of Shenzhen, China have entered into a strategic cooperation agreement. Mr. Chuck Kummeth - CEO of Bio-Techne and Mr. Yan Pingyi - Chairman of Micropoint Bioscience attended the meeting and signed a strategic cooperation agreement. Mr. Wang Bin -- Executive Vice President of Shenzhen Association of Medical Devices was present to witness this significant moment. Microfluidic technology is at the core development of the "lab on a chip" vision which will continue to drive advances in precision medicine. The ability to achieve miniaturization testing within a minimal sample volume requirement are at the heart of Point-of-Care devices that bring useful and diagnostic tests closer to the patient and make them easier to administer. As these two leading high-tech companies in the field of microfluidics, Micropoint Bioscience and Bio-Techne will further strengthen the technology integration in the field of microfluidics through this strategic cooperation, and develop companion diagnostic and precision diagnostic tools for doctors in China to provide better, more accurate and closer to patient diagnostic solutions that deliver better overall treatment. Chuck Kummeth, CEO of Bio-Techne remarked: "The synergies are obvious between the two Companies. Diagnostic decisions are increasingly being driven by cytokine and growth factors related to profiles in circulating body fluids. This creates the need for a testing platform which can accommodate more complex biomarker signatures. Having access to high-quality reagents to enable test menu expansion to address emerging diagnostic markets and needs is key to this endeavour." Yan Pingyi, Chairman of Micropoint Bioscience, added: "Micropoint is excited about this strategic cooperation. This collaboration will aim to develop diagnostic tools to monitor and identify cytokine releasing storm syndromes during immunotherapy. This will enable physicians to tailor their treatment decisions depending upon their severity of any adverse effects. This agreement leverages our respective strengths. We understand the China diagnostic market and have developed the necessary regulatory infrastructure to serve it. Having access to additional key reagents and an additional immunoassay test platform to address our market puts us in a strong position to succeed." About Micropoint Bioscience of Shenzhen, China Headquartered in Shenzhen and Santa Clara, USA, Micro-Point Biotechnology Co., Ltd. was listed on the National Equities Exchange and Quotations on January 7, 2016. Micropoint Bioscience is a leader in Microfluidics and MEMS (Micro-Electro-Mechanical System), and is dedicated to the development, manufacturing and sales of Lab on a Chip products based on MEMS technology. The company's many innovative technologies have been patented in the United States, Europe, China and other countries. About Bio-Techne Corporation Bio-Techne Corporation was registered in Minnesota, USA in 1981 and is listed on the NASDAQ Stock Exchange. The company and its subsidiaries focus on the development, production and sales of biotech products, blood calibrators and controllers. With the Advanced Cell Diagnostics and Exosome Diagnostics brands, Bio-Techne is now a leading supplier of quality consumables and instrumentation and molecular diagnostic solutions for the life sciences protein market. It's antibody products are used to functionalize both research and diagnostic instruments and are at the heart many biomarker analysis platforms. The Bio-Techne's Ella microfluidic instrument is a fully automated multi-analyte immunoassay platform which can deliver results in less than an hour. Source: Micropoint Bioscience of Shenzhen, China

  • When was Micropoint Bioscience founded?

    Micropoint Bioscience was founded in 2007.

  • Where is Micropoint Bioscience's headquarters?

    Micropoint Bioscience's headquarters is located at Block 6, Shenzhen.

  • What is Micropoint Bioscience's latest funding round?

    Micropoint Bioscience's latest funding round is IPO.

  • Who are the investors of Micropoint Bioscience?

    Investors of Micropoint Bioscience include Kaiwu Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.